DiaMedica Therapeutics DMAC 深 滬
已收盤 02-06 16:00:00 美东时间
8.14
+0.600
+7.96%
華盛通- 最 高8.24
- 今 開7.74
- 成交量 16.47万股
- 最 低 7.58
- 昨 收 7.54
- 總市值 4.36亿
- 52周最高 10.4195
- 市盈率 靜 --
- 換手率 0.31%
- 52周最低 3.19
- 委 比 -53.19%
- 總股本 5357.84万
- 歷史最高 10.88
- 量 比 0.90
- 振 幅 8.75%
- 歷史最低 1.12
- 每 手 1
- 風險率 1.71%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多DiaMedica Therapeutics Raises Capital via Share Offering
Diamedica Therapeutics ( ($DMAC) ) has issued an announcement. On December 19, ...
01-05 22:49
DiaMedica Therapeutics Completes Productive In-Person Pre-IND Meeting With FDA For Planned Study Evaluating DM199 In Preeclampsia
DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company developing novel treatments for preeclampsia (PE), fetal growth restriction (FGR) and acute ischemic stroke (AIS), today announced
2025-12-18 21:46
美股大行评级 | 花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级
花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级>>
2025-11-17 10:49
Cantor Fitzgerald Initiates Coverage On DiaMedica Therapeutics with Overweight Rating, Announces Price Target of $25
Cantor Fitzgerald analyst Josh Schimmer initiates coverage on DiaMedica Therapeutics (NASDAQ:DMAC) with a Overweight rating and announces Price Target of $25.
2025-11-14 22:29
DiaMedica Therapeutics Q3 EPS $(0.17), Inline
DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.17) per share which met the analyst consensus estimate. This is a 13.33 percent decrease over losses of $(0.15) per share from the same period last
2025-11-13 05:31
Earnings Scheduled For November 12, 2025
Companies Reporting Before The Bell • Hudbay Minerals (NYSE:HBM) is projected t...
2025-11-12 19:11
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Genprex (NASDAQ:GNPX) stock increased by 88.1% to $0.47 during Wednesd...
2025-10-15 20:09
DiaMedica Therapeutics Advances with Positive Trials and Funding
Diamedica Therapeutics ( ($DMAC) ) has released its Q2 earnings. Here is a brea...
2025-08-14 12:24
DiaMedica Therapeutics Q2 EPS $(0.18) Beats $(0.19) Estimate
DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.19) by 5.26 percent. This is a 38.46 percent decrease over losses of $(0.13) per share
2025-08-13 04:15
